This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F14%3A10290560%21RIV15-MSM-11110___/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n8http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n19http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F14%3A10290560%21RIV15-MSM-11110___
rdf:type
skos:Concept n18:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.3109/21681805.2013.814707
dcterms:description
Objective. The aim of this study was to evaluate the persistence of first line anticholinergic medication use by patients with overactive bladder (OAB). Data from a hospital outpatient database were matched with information obtained by a telephone survey of patients to determine which patients discontinued use of anticholinergic medication and to identify the reasons underlying discontinuation. Material and methods. The study group included 377 OAB patients (52 men, 325 women) with a mean age of 60.29 +/- 13.84 years. In total, 189 patients (50.1%) were treated with trospium (median dose 27.86 +/- 12.73 mg), 41 patients (10.9%) with propiverine (28.17 +/- 4.97 mg), nine patients (2.4%) with extended-release tolterodine (4.0 +/- 0 mg), 48 patients (12.7%) with solifenacin (5.94 +/- 1.97 mg) and 90 patients (23.9%) with fesoterodine (6.09 +/- 2.01 mg). Results. The median time for persistence with the first line anticholinergic treatment was 6.53 +/- 3.84 months. Persistence was significantly higher in patients treated with anticholinergic medication with an extended-release formulation than in patients treated with immediate-release anticholinergics. The most common reasons for termination of treatment were healing/resolution of symptoms (35.9%), low effectiveness (30.9%) and side-effects (23.7%). Conclusions. More than half of the OAB patients were not satisfied with their first line treatment. Other treatment options should be sought, such as changing the medication or dosage, or possibly combining treatments. Objective. The aim of this study was to evaluate the persistence of first line anticholinergic medication use by patients with overactive bladder (OAB). Data from a hospital outpatient database were matched with information obtained by a telephone survey of patients to determine which patients discontinued use of anticholinergic medication and to identify the reasons underlying discontinuation. Material and methods. The study group included 377 OAB patients (52 men, 325 women) with a mean age of 60.29 +/- 13.84 years. In total, 189 patients (50.1%) were treated with trospium (median dose 27.86 +/- 12.73 mg), 41 patients (10.9%) with propiverine (28.17 +/- 4.97 mg), nine patients (2.4%) with extended-release tolterodine (4.0 +/- 0 mg), 48 patients (12.7%) with solifenacin (5.94 +/- 1.97 mg) and 90 patients (23.9%) with fesoterodine (6.09 +/- 2.01 mg). Results. The median time for persistence with the first line anticholinergic treatment was 6.53 +/- 3.84 months. Persistence was significantly higher in patients treated with anticholinergic medication with an extended-release formulation than in patients treated with immediate-release anticholinergics. The most common reasons for termination of treatment were healing/resolution of symptoms (35.9%), low effectiveness (30.9%) and side-effects (23.7%). Conclusions. More than half of the OAB patients were not satisfied with their first line treatment. Other treatment options should be sought, such as changing the medication or dosage, or possibly combining treatments.
dcterms:title
Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients
skos:prefLabel
Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients
skos:notation
RIV/00216208:11110/14:10290560!RIV15-MSM-11110___
n3:aktivita
n11:V
n3:aktivity
V
n3:cisloPeriodika
1
n3:dodaniDat
n19:2015
n3:domaciTvurceVysledku
n9:4073657
n3:druhVysledku
n7:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
36248
n3:idVysledku
RIV/00216208:11110/14:10290560
n3:jazykVysledku
n4:eng
n3:klicovaSlova
persistence; overactive bladder; Anticholinergics
n3:klicoveSlovo
n16:Anticholinergics n16:persistence n16:overactive%20bladder
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[DD6AFB79C924]
n3:nazevZdroje
Scandinavian Journal of Urology
n3:obor
n14:FE
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
7
n3:rokUplatneniVysledku
n19:2014
n3:svazekPeriodika
48
n3:tvurceVysledku
Petzel, Martin Tvrdik, Josef Sykora, Radek Nemec, David Skoupá, Jana Gärtner, Marcel Krhut, Jan
n3:wos
000332420100011
s:issn
2168-1805
s:numberOfPages
5
n8:doi
10.3109/21681805.2013.814707
n12:organizacniJednotka
11110